Gilead Brings In Sanofi’s Dietmar Berger To Reset Drug Development

The oncology drug development veteran has been hired by former colleague Daniel O’Day as Gilead looks to improve its R&D hit rate.

Gilead
Gilead adds in liver with CymaBay acquisition • Source: Shutterstock: Tada Images

Gilead has poached Sanofi’s Dietmar Berger to be its new chief medical officer and oversee its global development and medical affairs organizations, as it looks to reset after a string of late-stage drug failures.

Berger is currently chief medical officer and global head of development at Paris-based Sanofi, but...

More from Executives On The Move

More from Scrip